Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells

9 Aug 2012

Abstract excerpt

Prostate cancer is the most common noncutaneous malignancy in men. The prostate stem cell Ag (PSCA) is a promising target for immunotherapy of advanced disease. Based on a novel mAb directed to PSCA, we established and compared a series of murine and humanized anti-CD3-anti-PSCA single-chain bispecific Abs. Their capability to redirect T cells for killing of tumor cells was analyzed. During these studies, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Xenotransplantation and immune response

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22875801
DOI: 10.4049/jimmunol.1200341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T CellsPMID 22875801Read ↗

A multifunctional T-cell engager containing CD80 enhances prostate cancer treatmentSemantic proximity Read ↗

Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors.Semantic proximity Read ↗

Targeting human γδ T cells as a potent and safe alternative to pan-T cells bispecific cell engagersSemantic proximity Read ↗

PSMA-Specific Car-Engineered T Cells for Prostate Cancer: CD28 outperforms combined CD28-41BB “Super- stimulation”Semantic proximity Read ↗

Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing TumorsSemantic proximity Read ↗

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.Semantic proximity Read ↗

Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer GrowthSemantic proximity Read ↗

Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous ImmunitySemantic proximity Read ↗

Human plasma cells engineered to secrete bispecifics drive effective <i>in vivo</i> leukemia killingSemantic proximity Read ↗

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate CancerSemantic proximity Read ↗

Functional comparison of single-chain and two-chain anti-CD3-based bispecific antibodies in gene immunotherapy applicationsSemantic proximity Read ↗

Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.